Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.59 |
| ▸ | HRH1 | P35367 | 10/20 | 0.59 |
| ▸ | HTR2C | P28335 | 9/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11898647 | 0.99 | HTR2A (0.58) | HTR2AHRH1HTR2CHTR2BDRD2 | |
| SCHEMBL11899342 | 0.96 | HTR2A (0.58) | HTR2AHRH1HTR2CHTR2BDRD2 | |
| SCHEMBL11899311 | 0.94 | HTR2A (0.55) | HTR2AHRH1HTR2CHTR2BDRD2 | |
| Hydrochloric Acid SCHEMBL11898706 | 0.93 | HTR2A (0.54) | HTR2AHRH1HTR2CHTR2BDRD2 | |
| SCHEMBL11899356 | 0.92 | HTR2C (0.64) | HTR2AHRH1HTR2CHTR2BDRD2 | |
| Hydrochloric Acid SCHEMBL11899140 | 0.92 | HTR2C (0.63) | HTR2AHRH1HTR2CHTR2BDRD2 | |
| SCHEMBL11899003 | 0.91 | HTR2A (0.61) | HTR2AHRH1HTR2CHTR2BDRD2 | |
| SCHEMBL11898709 | 0.91 | HTR2A (0.53) | HTR2AHRH1HTR2CHTR2BDRD2 | |
| SCHEMBL11914117 | 0.91 | HTR2C (0.60) | HTR2AHRH1HTR2CHTR2BDRD2 | |
| SCHEMBL11898738 | 0.90 | HTR2A (0.58) | HTR2AHRH1HTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683719-B1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | LILLY CO ELI (US) | 2015-03-18 | — | — | EP | claimed |
| EP-2683719-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | Eli Lilly and Company (US) | 2014-01-15 | — | — | EP | claimed |
| US-8314092-B2 | Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | claimed |
| WO-2012109011-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-16 | — | — | WO | claimed |
| US-20120202797-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-09 | — | — | US | claimed |
| EP-2683719-B1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | LILLY CO ELI (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2683719-B1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | LILLY CO ELI (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2683719-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | Eli Lilly and Company (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8314092-B2 | Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314092-B2 | Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314092-B2 | Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| WO-2012109011-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012109011-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202797-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202797-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120201749-A1 | NP-1 Antagonists and Their Therapeutic Use | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120202797-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120201749-A1 | NP-1 Antagonists and Their Therapeutic Use | NPFFR1, NR0B1, NR0B2 | HTR2A 1362/4885HRH1 465/4885HTR2C 1564/4885 |
| US-20120202797-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | HTR2A, HTR1A, HTR2C | HTR2A 1/4885HRH1 16/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.